ANAKINRA

Names

[ Name ]:
ANAKINRA

[Synonym ]:
(7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-({[(2,2-dimethylpropanoyl)oxy]methoxy}imino)acetyl]amino}-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-[[(2,2-dimethyl-1-oxopropoxy)methoxy]imino]-1-oxoethyl]amino]-3-ethenyl-8-oxo-, (7R)-

Biological Activity

[Description]:

Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Anakinra is the first biological agent to block the pro-inflammatory effects[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[Target]

IL-1R[1].

[In Vivo]

Combined etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, I.P. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice[2]. Anakinra enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan[3].

[References]

[1]. Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16(4):303-11; discussion 313-4.

[2]. McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12(2):322-9.

[3]. Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res. 2010 Oct;30(10):3959-65.

Chemical & Physical Properties

[ Density]:
1.6±0.1 g/cm3

[ Molecular Formula ]:
C₇₅₉H₁₁₈₆N₂₀₈O₂₃₂S₁₀

[ Molecular Weight ]:
509.556

[ Exact Mass ]:
509.103882

[ LogP ]:
2.69

[ Index of Refraction ]:
1.705

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.